Clinical Trial Update: A Study in Participants With Sarcoidosis-associated Pulmonary Hypertension (SAPH) to Assess the Efficacy and Safety of Oral Selexipag [Phase 2]

View source ↗

Summary

Phase 2 study evaluating oral selexipag for Sarcoidosis-associated Pulmonary Hypertension was terminated, and results were posted in May 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Hypertension
• Sarcoidosis

Drugs mentioned

• Uptravi (selexipag)

Snippet

Sponsor: Actelion | Conditions: Sarcoidosis-associated Pulmonary Hypertension | Phase 2 | Status: TERMINATED | Results posted: 2024-05-08